{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T16:46:23.791836+00:00","company":{"ticker":"PEN","cik":1321732,"company_name":"Penumbra Inc"},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"4506dfa7f1524bfe14891b5175b0ddf5c2220939","cik":1321732,"ticker":"PEN","company_name":"Penumbra Inc","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$32.6 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$374.8 million"},"claim":"Penumbra Inc reported first quarter ended March 31, 2026 results: revenue $374.8 million, net income $32.6 million.","evidence_excerpt":"Penumbra, Inc. Reports First Quarter 2026 Financial Results ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026. • Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025. • Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025. • Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025. • Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025. • Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pendin","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001321732-26-000018","anchor_url":"https://secwatch.observer/filing/0001321732-26-000018#claim-4506dfa7f1524bfe14891b5175b0ddf5c2220939","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1321732/000132173226000018/0001321732-26-000018-index.htm"},{"fact_type":"material_agreement","fact_key":"c783b1e0bf020ef172884b04abc7c08b53d0d5fa","cik":1321732,"ticker":"PEN","company_name":"Penumbra Inc","filed_at":"2026-01-15T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"Boston Scientific Corporation","effective_date":"2026-01-14","item_codes_triggered":["1.01"],"value_text":null},"claim":"Penumbra Inc entered into Agreement and Plan of Merger with Boston Scientific Corporation (effective 2026-01-14).","evidence_excerpt":"On January 14, 2026, Penumbra, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) among the Company, Boston Scientific Corporation, a Delaware corporation (“Parent”), and Pinehurst Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Parent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950103-26-000523","anchor_url":"https://secwatch.observer/filing/0000950103-26-000523#claim-c783b1e0bf020ef172884b04abc7c08b53d0d5fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1321732/000095010326000523/0000950103-26-000523-index.htm"},{"fact_type":"executive_change","fact_key":"bd24e38750","cik":1321732,"ticker":"PEN","company_name":"Penumbra Inc","filed_at":"2025-02-21T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2025-04-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Don Kassing retired as Director at Penumbra Inc.","evidence_excerpt":"On February 14, 2025, Don Kassing, a member of the Board of Directors (the “Board”) of Penumbra, Inc. (the “Company”), notified the Company that he will retire from the Board effective April 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001321732-25-000036","anchor_url":"https://secwatch.observer/filing/0001321732-25-000036#claim-bd24e38750","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1321732/000132173225000036/0001321732-25-000036-index.htm"},{"fact_type":"earnings_release","fact_key":"c8e74ac543ee5068a1c598fa503ffb4562ca6f5c","cik":1321732,"ticker":"PEN","company_name":"Penumbra Inc","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first fiscal quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$278.7 million"},"claim":"Penumbra Inc reported the first fiscal quarter ended March 31, 2024 results: revenue $278.7 million. Guidance reaffirmed.","evidence_excerpt":"Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. • Revenue of $278.7 million in the first quarter of 2024, an increase of 15.4% or 15.2% in constant currency 1 , compared to the first quarter of 2023. • U.S. thrombectomy revenue of $150.3 million in the","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001321732-24-000058","anchor_url":"https://secwatch.observer/filing/0001321732-24-000058#claim-c8e74ac543ee5068a1c598fa503ffb4562ca6f5c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1321732/000132173224000058/0001321732-24-000058-index.htm"}]}